BioDot Inc. of Irvine had plans to scale in 2020. It didn’t anticipate a global pandemic, which drove demand higher than ever before for its ultra low-volume dispensers that are used to dispense ...
IRVINE, Calif.--(BUSINESS WIRE)--To support increasing demand globally for COVID-19 testing, BioDot has compressed production times for most new lateral flow dispensing platforms from months to four ...
Biodot, which started operations in 1994, manufactures automated ultra-low-volume fluid dispensing systems for labs that make antibody or serology tests. These tests are indicators of immune responses ...
BioDot, Inc., a supplier of nanoliter dispensing systems has entered a strategic alliance with Berlin-based Scienion AG, a picoliter liquid handling specialist, to accelerate the development of ...
Artemis Capital Partners has acquired Irvine, California-based BioDot Inc, a maker of automated ultralow volume fluid dispensing systems. No financial terms were disclosed. IRVINE, Calif., April 9, ...
BUFFALO, N.Y. and IRVINE, Calif., April 24, 2025 /PRNewswire/ -- Empire Genomics, a Biocare Medical company and leader in molecular diagnostics, is proud to announce a strategic partnership with ...
BioDot Inc., an Irvine-based medical device maker involved in testing for the coronavirus, was acquired March 27 for an undisclosed amount by Boston-based Artemis Capital Partners. The company, ...
CAMBRIDGE, Ont. — ATS Automation Tooling Systems Inc. has signed a deal to buy U.S. company BioDot Inc., a manufacturer of automated fluid dispensing systems, for $106 million. California-based BioDot ...
ATS entered into a definitive agreement and announced its intention to acquire BioDot on April 14, 2021. CAMBRIDGE — On June 1, ATS Automation Tooling Systems Inc., an automation solutions provider, ...
BOSTON , June 17, 2021 /PRNewswire/ -- Artemis Capital Partners ("Artemis"), a Boston -based private equity firm focused exclusively on partnering with differentiated industrial technology companies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results